CEACAM5 and non-small cell lung carcinoma: In accordance with CEACAM5 overexpression in lung tumor tissues, the anti-CEACAM5 antibody drug-conjugate (ADC) SAR408701 is being evaluated in non-small cell lung cancer (NSCLC) with different interventions in clinical trials (16, 20).